These data will be discussed during the conference call presenting Nanobiotix’s third quarter results, at 8 a.m. EST / 2 p.m. CET.
• Data from the entire dose escalation part of the immunotherapy phase 1 clinical trial show that treatment with NBTXR3, activated by radiotherapy and associated with an anti-PD 1, is feasible and well tolerated The dose recommended for Phase 2 was established at 33% of the tumor volume in the 3 cohorts.
• Results at the cutoff date (August 22, 2022) included the analysis of 5 additional patients among the 21 evaluable patients. These results continue to suggest local control and stimulation of the immune response independent of prior anti-PD-1 immunotherapy.
• Regression of all target lesions was observed in 71.43% of evaluable patients (15/21) and regression of more than 30% was observed in 42.86% of evaluable patients (9/21) .
• Regression was observed in 66.66% of evaluable patients whose cancer was resistant to anti-PD-1 (10/15).
• Systemic disease control was durable and was maintained for more than 6 months in 38.10% of evaluable patients (8/21).